Knowledge Library

Enabling Technology for Targeted Protein Degradation

Summary Traditional small molecule therapeutic mechanisms have recently been augmented by a new strategy to specifically manipulate the levels of disease-related proteins. By employing bifunctional molecules, we can hijack endogenous cellular degradation mechanism for targeted degradation of a disease-related protein. Bifunctional molecules consisting of a ligand that binds to an E3 ligase, connected by a …Read More >

Resource Type: Latest Science
Resource Topic: Biochemical Assays Biophysical Assays Cell-based Assays Discovery Chemistry Small Molecules Target Identification and Validation Targeted Protein Degradation

VIEW

Establishment of KRAS-G12C inhibitor induced resistant tumor models enable the development of new generation KRAS-G12C inhibitors and combinatorial strategies

Activating KRAS mutations, including G12C and G12D, are detected in approximately 25% of human cancers. The most common KRAS mutation is G12C, which comprises nearly 15% of lung adenocarcinomas, 8% of colorectal carcinomas and 4% of pancreatic adenocarcinomas. AMG-510 from Amgen and MRTX849 from Mirati Therapeutics, both targeting the KRASG12C mutant, have shown encouraging results …Read More >

Resource Type: Poster
Resource Topic: Biochemical Assays Oncology Phenotypic Assays Small Molecules Target Identification and Validation Tumor Models

VIEW

Targeted Protein Degradation Platform

Integrated Services BIOLOGY & PHARMACOLOGY BINARY/TERNARY COMPLEX FORMATION Biochemical & Biophysical Assays Biochemical binding assay Cellular Assays TARGET UBIQUITINATION & DEGRADATION In vitro Assays-Target ubiquitination Target degradation assay PK/PD Animal Disease Model Evaluation CHEMISTRY Specific virtual library design Compound synthesis Conjugation and all type of custom syntheses from milligram to kilogram scale Purification and analytical …Read More >

Resource Type: Brochure
Resource Topic: Biochemical Assays Biophysical Assays Cell-based Assays Discovery Chemistry Hit-to-Lead Lead Optimization Small Molecules Targeted Protein Degradation

VIEW

WuXi Oncology and Immuno-Oncology Services

Integrated Oncology and Immuno-oncology Platform to Enable Translational Science from Drug Discovery to Clinical Biomarker Oncology Services CRISPR/Cas9 Gene Editing In Vitro Assay and HTS Tumor models Tumor Cell Panel and Screening Immunology and Immuno-oncology Platform Clinical Biomarker Immunology Services Ligand-receptor binding assays Cellular functional assays Assays for innate immunity pathways: macrophage, MDSC, NK, DC, …Read More >

Resource Type: Brochure
Resource Topic: Antibodies Biochemical Assays Biomarkers Cell-based Assays Cells and Protein Science Chemical Biology and Proteomics Gene Therapies High-throughput screening (HTS) Hit-to-Lead Immunology in vitro biology in vivo Pharmacology Lead Optimization Oncology Screening Libraries Small Molecules Target Identification and Validation Target-Specific Assays Targeted Protein Degradation Tumor Models

VIEW

Virology and Viral Vector Platforms

WuXi virology platforms: Immunology, Anti viral, Viral Vector, Oligo-nucleotide, Clinical and Immunology in vitro screening and profiling in vivo efficacy clinical virology Liver-specific viruses | Respiratory viruses | Herpes viruses | Other viruses

Resource Type: Brochure
Resource Topic: Biochemical Assays Biomarkers Candidate Selection CAR-T Cell Cell-based Assays Cells and Protein Science in vivo Pharmacology in vivo Toxicology Infectious Diseases Lead Optimization Oncolytic Viruses Phenotypic Assays Safety and Early Toxicity

VIEW

WuXi AppTec in vitro Safety Pharmacology Profiling

Comprehensive in vitro Off-target Screening Services WuXi Discovery Biology provides in vitro Safety Pharmacology services to identify potential off-target liabilities. Three choices can be selected: WuXi Biology Mini Safety Panel “WuXi Mini 44” A primary safety panel, which is designed to identify compounds with the highest risk because it contains targets associated with the most …Read More >

Resource Type: Brochure
Resource Topic: Biochemical Assays Cell-based Assays Lead Optimization Safety and Early Toxicity Target-Specific Assays

VIEW

in vitro Toxicity Services

Identify potential liability issues in early stages of drug discovery Cardiotoxicity hERG and other ion channel test Stem cell derived cardiomyocyte test on MEA General Cytotoxicity Cell Viability Assay Apoptosis Assay CellTox ™ Green Cytotoxicity Assay ApoTox Glo ™ Triplex Assay Mitochondrial ToxicityMitochondrial Membrane Potential Assay Mitochondrial Reactive Oxygen Species (ROS) Assay Oxygen Consumption Assay: …Read More >

Resource Type: Brochure
Resource Topic: Biochemical Assays Cell-based Assays Hit-to-Lead in vitro biology Lead Optimization Safety and Early Toxicity

VIEW

HBV Discovery Services

A Platform Supporting HBV Drug Discovery A broad assay platform for the discovery of agents for the treatment of chronic HBV infection. Services for assay establishment and validation, compound screening and profiling, and support of preclinical studies and clinical trials. Drug screening using HBV producing cell lines HBV infectious assays Reporter assays Core protein expression …Read More >

Resource Type: Brochure
Resource Topic: Biochemical Assays Cell-based Assays in vitro biology in vivo Pharmacology Infectious Diseases Lead Optimization

VIEW


Resource Topics
× peptide, amino acid

Contact An Expert Today!